Editors’ Picks, April 2024: Targeting Metabolism, KRAS, and More
April picks include metabolic interventions for acute myeloid leukemia, new inhibitors of KRAS signaling, and more.
Progress Against Cancer
April picks include metabolic interventions for acute myeloid leukemia, new inhibitors of KRAS signaling, and more.
The FDA approved the BRAF inhibitor tovorafenib for pediatric patients with certain Genetic alterations. The U.S. Food and Drug Administration (FDA) has approved tovorafenib (Ojemda) for the treatment of pediatric patients aged 6 months...
The FDA has approved lutetium Lu 177 dotatate for children 12 years or older with some gastroenteropancreatic neuroendocrine tumors. The U.S. Food and Drug Administration (FDA) has approved lutetium Lu 177 dotatate (Lutathera) for...
The FDA has approved nogapendekin alfa inbakicept-pmln, which stimulates immune cells to fight bladder cancer. The U.S. Food and Drug Administration (FDA) has approved nogapendekin alfa inbakicept-pmln (Anktiva) in combination with Bacillus Calmette-Guérin (BCG),...
A urine test may help grade prostate cancers without biopsies, and states look for savings and better health in palliative care.
The FDA has approved the ALK inhibitor alectinib for surgically resectable NSCLC. The U.S. Food and Drug Administration (FDA) has approved alectinib (Alecensa) for use after the surgical removal of a non-small cell lung...
Researchers at the AACR Annual Meeting 2024 presented the latest findings regarding two personalized neoantigen cancer vaccines.
A poster at the AACR Annual Meeting 2024 examined a video that increased awareness of prostate cancer.
More cancer patients are enrolling in clinical trials, and sentinel node biopsies alone may be adequate for some early-stage breast cancers.
Fam-trastuzumab deruxtecan-nxki was approved for HER2-positive tumors, regardless of the tissue of origin. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to fam-trastuzumab deruxtecan-nxki (T-DXd, Enhertu) for adult patients with unresectable...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More